PL2846806T3 - Leczenie depresji oddechowej - Google Patents

Leczenie depresji oddechowej

Info

Publication number
PL2846806T3
PL2846806T3 PL13728235T PL13728235T PL2846806T3 PL 2846806 T3 PL2846806 T3 PL 2846806T3 PL 13728235 T PL13728235 T PL 13728235T PL 13728235 T PL13728235 T PL 13728235T PL 2846806 T3 PL2846806 T3 PL 2846806T3
Authority
PL
Poland
Prior art keywords
treatment
respiratory depression
respiratory
depression
Prior art date
Application number
PL13728235T
Other languages
English (en)
Inventor
David Cavalla
Original Assignee
Numedicus Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numedicus Limited filed Critical Numedicus Limited
Publication of PL2846806T3 publication Critical patent/PL2846806T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13728235T 2012-05-11 2013-05-10 Leczenie depresji oddechowej PL2846806T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1208315.0A GB201208315D0 (en) 2012-05-11 2012-05-11 Pharmaceutical methods and compositions
PCT/GB2013/051213 WO2013167906A1 (en) 2012-05-11 2013-05-10 Treatment of respiratory depression
EP13728235.6A EP2846806B1 (en) 2012-05-11 2013-05-10 Treatment of respiratory depression

Publications (1)

Publication Number Publication Date
PL2846806T3 true PL2846806T3 (pl) 2018-03-30

Family

ID=46458692

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13728235T PL2846806T3 (pl) 2012-05-11 2013-05-10 Leczenie depresji oddechowej

Country Status (12)

Country Link
US (1) US9610291B2 (pl)
EP (1) EP2846806B1 (pl)
JP (1) JP2015520145A (pl)
CA (1) CA2868228C (pl)
DK (1) DK2846806T3 (pl)
ES (1) ES2656889T3 (pl)
GB (1) GB201208315D0 (pl)
HU (1) HUE036419T2 (pl)
NO (1) NO2846806T3 (pl)
PL (1) PL2846806T3 (pl)
PT (1) PT2846806T (pl)
WO (1) WO2013167906A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229258B2 (en) 2014-03-12 2020-01-30 The Trustees Of Columbia University In The City Of New York A new class of Mu-Opioid receptor agonists
US10844027B2 (en) 2015-09-16 2020-11-24 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
WO2024206520A1 (en) * 2023-03-27 2024-10-03 Tonix Pharmaceuticals Holding Corp. (s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1269551A (en) 1969-03-27 1972-04-06 Science Union & Cie New tricyclic derivatives and process for their manufacture
US3758528A (en) 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US3821249A (en) 1970-03-13 1974-06-28 En Nom Collectif Science Union Dibenzothiazefin derivatives
FR2594827B1 (fr) 1986-02-21 1988-05-20 Adir Nouveau derive tricyclique denomme acide ((chloro-3 methyl-6 dioxo-5,5 dihydro-6, 11 dibenzo (c,f) thiazepine (1,2) yl-11 amino)-5 pentazoique, son procede de preparation et les compositions pharmaceutiques qui le contiennent
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2747921B1 (fr) 1996-04-24 1998-10-30 Adir Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
FR2807039A1 (fr) 2000-03-31 2001-10-05 Adir NOUVEAU PROCEDE DE PREPARATION DE LA 11-AMINO-3-CHLORO-6,11- DIHYDRO-5,5-DIOXO-6-METHYL-DIBENZO[c,f][1,2]-THIAZEPINE ET APPLICATION A LA SYNTHESE DE LA TIANEPTINE

Also Published As

Publication number Publication date
EP2846806A1 (en) 2015-03-18
CA2868228C (en) 2021-03-09
ES2656889T3 (es) 2018-02-28
WO2013167906A1 (en) 2013-11-14
HUE036419T2 (hu) 2018-07-30
EP2846806B1 (en) 2017-12-13
JP2015520145A (ja) 2015-07-16
US20150141405A1 (en) 2015-05-21
CA2868228A1 (en) 2013-11-14
DK2846806T3 (da) 2018-01-29
NO2846806T3 (pl) 2018-05-12
US9610291B2 (en) 2017-04-04
GB201208315D0 (en) 2012-06-27
PT2846806T (pt) 2018-01-29

Similar Documents

Publication Publication Date Title
HK1207574A1 (en) Treatment of myelosuppression
PL2890257T3 (pl) Inhalator
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HK1203424A1 (en) Inhaler
AU345543S (en) Inhaler
GB2506621B (en) Respiratory mask
GB201506561D0 (en) Treatment of amblyopia
PL2900303T3 (pl) Inhalator
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
GB201309274D0 (en) Treatment Of Fuel
EP2841098A4 (en) NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
HUE036419T2 (hu) Légzõszervi depresszió kezelése
GB201207907D0 (en) Treatment of depression
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201208505D0 (en) Treatment of skin condition
GB201204645D0 (en) Treatment of disease
GB201208503D0 (en) Treatment of a skin condition
GB201218263D0 (en) Treatment of autism
GB201201778D0 (en) Treatment of inflammatory respiratory disease